Wings Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 7.26 Cr
as on 07-11-2024
- Paid Up Capital ₹ 1.80 Cr
as on 07-11-2024
- Company Age 37 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 4.97 Cr
as on 07-11-2024
- Revenue -8.99%
(FY 2023)
- Profit -60.88%
(FY 2023)
- Ebitda -23.42%
(FY 2023)
- Net Worth -7.40%
(FY 2023)
- Total Assets -7.66%
(FY 2023)
About Wings Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.26 Cr and a paid-up capital of Rs 1.80 Cr.
The company has closed loans amounting to ₹4.97 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Rajinder Arora and Deepanshu Arora serve as directors at the Company.
- CIN/LLPIN
U74899DL1987PTC027499
- Company No.
027499
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Apr 1987
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Wings Pharmaceuticals Pvt Ltd offer?
Wings Pharmaceuticals Pvt Ltd offers a wide range of products and services, including Antipyretic Medication, Paracetamol Tablets, Allopathic Cough Syrup, Dextromethorphan Cough Syrup, Nutraceuticals, Protein Supplement, Diclofenac, Diclofenac Sodium Tablet, Candy & Jelly, Flavoured Candies.
Who are the key members and board of directors at Wings Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajinder Arora  | Director | 26-Mar-1991 | Current |
| Deepanshu Arora | Director | 31-Mar-2022 | Current |
Financial Performance of Wings Pharmaceuticals.
Wings Pharmaceuticals Pvt Ltd, for the financial year ended 2023, experienced Minor drop in revenue, with a 8.99% decrease. The company also saw a substantial fall in profitability, with a 60.88% decrease in profit. The company's net worth dipped by a decrease of 7.4%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Wings Pharmaceuticals?
In 2022, Wings Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 01 May 2012 | ₹4.50 Cr | Satisfied |
Hdfc Bank Limited Creation Date: 19 Feb 2007 | ₹0.73 M | Satisfied |
Bank Of India Creation Date: 06 Feb 1998 | ₹4.00 M | Satisfied |
How Many Employees Work at Wings Pharmaceuticals?
Wings Pharmaceuticals has a workforce of 339 employees as of Nov 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Wings Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Wings Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
